Sosei Heptares Archives

Home Sosei Heptares

Latest Posts

News and Trends 20 Jul 2023

Sosei Heptares hails ‘transformational’ acquisition

Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and…

July 20, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment…

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated…

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses…

December 8, 2022 - 3 minutesmins - By Jim Cornall

More News! 9 Nov 2022

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision…

November 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the US Food and Drug Administration (FDA) and a study can now go ahead. Neurocrine Biosciences…

August 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the…

August 2, 2022 - 2 minutesmins - By Liza Laws

Beyond Biotech - the podcast from Labiotech

View More

Newsletter Signup - Sidebar

"*" indicates required fields

Resources

Categories

The latest news on

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

Americas

Asia Pacific

Europe

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Company

Join Us

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering